Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) Head to Head Review

Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Aligos Therapeutics and Compugen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,283.19%	-114.34%	-64.58%
Compugen	2.67%	2.62%	1.36%

Risk and Volatility

Aligos Therapeutics has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.98, suggesting that its share price is 198% more volatile than the S&P 500.

Insider and Institutional Ownership

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Aligos Therapeutics and Compugen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$3.95 million	16.66	-$87.68 million	($20.90)	-0.51
Compugen	$27.86 million	5.03	-$18.75 million	($0.16)	-9.81

Compugen has higher revenue and earnings than Aligos Therapeutics. Compugen is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Aligos Therapeutics and Compugen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	0	0	1	0	3.00
Compugen	0	0	2	0	3.00

Aligos Therapeutics presently has a consensus target price of $70.00, suggesting a potential upside of 551.16%. Compugen has a consensus target price of $4.00, suggesting a potential upside of 154.78%. Given Aligos Therapeutics’ higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Compugen.

Summary

Compugen beats Aligos Therapeutics on 10 of the 13 factors compared between the two stocks.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.